This study is being conducted to evaluate the safety and effectiveness of a new medication called EL219 compared to the current standard treatment for patients with a suspected Invasive Mould Infection. An invasive mould infection occurs when certain types of fungi, which are microscopic organisms, grow deep inside the body and cause serious illness. The current standard treatment involves using Amphotericin B, Liposome through an intravenous line, which is a tube placed in a vein to deliver fluids directly into the bloodstream, followed by a medication called Voriconazole taken by mouth.

During the study, participants will be assigned to receive either the new experimental drug EL219 or the standard medications. To ensure the results are unbiased, a double-blind method is used, meaning neither the patients nor the medical staff know which specific treatment is being administered. In this process, some participants may receive a placebo, which is an inactive substance used for comparison. The course of the study involves monitoring the participants over a period of time to see how they respond to the treatments and to track any side effects.